RxDoctor Payments Data

Sarah Jones, APRN

Nurse Practitioner · Little Rock, ARNPI 1083154512

Payments from drug & device makers

$1,898in general payments, 2019–2025

Across 43 payments — averaging $44.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$935
  • Abbott$427
  • Neurocrine Biosciences, Inc.$139
  • Pfizer$67
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$62
  • Boston Scientific$52
  • plus $216 from 10 others

What the payments were for

  • Consulting fees$93549%
  • Food & beverage$96351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,898 in reported general payments places this provider in the 80th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$220,457
Medicare patients
1,514
Services billed
6,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$147,157
EntrestoSacubitril/Valsartan91$73,578
XareltoRivaroxaban34$34,451
MultaqDronedarone Hcl18$20,546
Dofetilide30$5,252
Mexiletine Hcl32$2,322
Metoprolol Succinate142$1,612
Potassium Chloride97$1,377
Flecainide Acetate18$853
SotalolSotalol Hcl29$709
Carvedilol62$450
Losartan Potassium70$438
Amiodarone Hcl34$379
Hydralazine Hcl17$377
Furosemide66$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$147,157158 claims
NovartisEntresto$19$73,57891 claims
Johnson & JohnsonXarelto$22$34,45134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →